DAWNRAYS PHARMA News

DAWNRAYS PHARMA: SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE DISPOSAL OF INTERESTS IN A JOINT VENTURE COMPANY

Mar 4 07:41 ET

DAWNRAYS PHARMA: DISCLOSEABLE TRANSACTION-DISPOSAL OF INTERESTS IN A JOINT VENTURE COMPANY

Feb 8 17:49 ET

DAWNRAYS PHARMA: DISCLOSEABLE TRANSACTION - PROVISION OF FINANCIAL ASSISTANCE

Oct 24, 2022 07:27 ET

DAWNRAYS PHARMA: (1) DISCLOSEABLE TRANSACTION-DISPOSAL OF EQUITY INTERESTS IN THE TARGET COMPANY; (2) UPDATE ON GAIN ON PREVIOUS DISPOSAL

Jan 26, 2022 08:21 ET

DAWNRAYS PHARMA: DISCLOSEABLE TRANSACTION - PROVISION OF FINANCIAL ASSISTANCE

Feb 2, 2021 08:10 ET

DAWNRAYS PHARMA: UPDATE ON JOINT VENTURE COMPANY-EARLY COMPLETION OF PATIENT ENROLLMENT IN PHASE IIB CLINICAL TRIAL FOR EBRONUCIMAB (PCSK9 INHIBITORS) FOR TREATING PATIENTS SUFFERING FROM HIGH- OR VERY HIGH-RISK HYPERCHOLESTEROLEMIA IN THE PRC

Dec 2, 2020 09:53 ET

DAWNRAYS PHARMA: DISCLOSEABLE TRANSACTION-CONSTRUCTION AGREEMENTS

Aug 14, 2020 10:54 ET

DAWNRAYS PHARMA: DISCLOSEABLE TRANSACTION -CONSTRUCTION AGREEMENT

Jun 25, 2020 07:18 ET

DAWNRAYS PHARMA: UPDATE ON JOINT VENTURE COMPANY AND SUPPLEMENTAL AGREEMENT TO JV AGREEMENT

Jun 24, 2020 10:36 ET

DAWNRAYS PHARMA: DISCLOSEABLE TRANSACTION MARKETING AUTHORIZATION HOLDER (MAH) IN RESPECT OF FEBUXOSTAT

Dec 24, 2019 09:55 ET

DAWNRAYS PHARMA: DISCLOSEABLE TRANSACTION-COMPLETION OF THE ACQUISITION OF TOP FIELD LIMITED

May 7, 2019 09:04 ET

DAWNRAYS PHARMA: UPDATE TO DISCLOSEABLE TRANSACTION IN RELATION TO THE ACQUISITION OF TOP FIELD LIMITED

Apr 30, 2019 07:10 ET